The Health and Human Services (HHS) Office of Inspector General (OIG) Work Plan describes audits, reviews and other work statutorily required or otherwise undertaken by the OIG. Monthly updates to the OIG Work Plan can be found on the Recently Added page. All current Work Plan items are available on the Active Work Plan Items page.
Sixteen new items were added to the OIG Work Plan in November 2019:
--> Scroll to see full table data
| Announced |
Agency |
Title |
Component |
Report Number(s) |
| November 2019 |
Centers for Medicare & Medicaid Services |
Medicaid Concurrent Eligibility |
Office of Audit Services |
W-00-19-31539 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Additional Programming Code for Toolkit: Using Data Analysis To Calculate Opioid Levels and Identify Patients at Risk of Misuse or Overdose |
Office of Evaluation and Inspections |
OEI-02-17-00561 |
| November 2019 |
OS, ACF, AHRQ, CDC, FDA, HRSA, NIH, OIG |
Audit of HHS Information Technology Recovery Readiness |
Office of Audit Services |
W-00-20-42025 |
| November 2019 |
Administration for Children and Families |
Review of Office of Refugee Resettlement’s Awarding of a No-Bid Contract for the Unaccompanied Alien Children Program |
Office of Audit Services |
W-00-20-20001 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2020 |
Office of Evaluation and Inspections |
OEI-03-20-00060 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2019 |
Office of Evaluation and Inspections |
OEI-03-20-00070 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2019 |
Office of Evaluation and Inspections |
OEI-03-20-00050 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2019 |
Office of Evaluation and Inspections |
OEI-03-20-00040 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Medicare Payments for Stelara |
Office of Evaluation and Inspections |
OEI-BL-19-00500 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2018 Average Sales Prices |
Office of Evaluation and Inspections |
OEI-03-20-00130 |
| November 2019 |
Indian Health Service |
Review of Background Verification Process at Tribally Operated Health Facilities |
Office of Audit Services |
W-00-20-51001 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Recommendation Followup Memo: Excluding Noncovered Versions When Setting Payment for Part B Drugs |
Office of Evaluation and Inspections |
OEI-BL-20-00100 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Medicare Advantage Organizations’ Collection of Ordering Provider Identifiers |
Office of Evaluation and Inspections |
OEI-03-19-00430 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Fiscal Year 2020 OIG Oversight of Medicaid Fraud Control Units |
Office of Evaluation and Inspections |
OEI-06-19-00110, OEI-06-19-00510, OEI-12-19-00450, OEI-12-19-00170, OEI-12-19-00530 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Medicaid Fraud Control Units Fiscal Year 2020 Annual Report |
Office of Evaluation and Inspections |
OEI-09-20-00110 |
| November 2019 |
Centers for Medicare & Medicaid Services |
Medicare Advantage Risk-Adjustment Data – Targeted Review of Documentation Supporting Specific Diagnosis Codes |
Office of Audit Services |
W-00-20-35079 |
--> Scroll to see full table data
Health care and life sciences companies potentially impacted by these OIG Work Plan items should evaluate these items carefully. These items should be considered when conducting a corporate risk mitigation assessment or other compliance enhancements.
[View source.]
